Inhibitor Therapeutics, Inc.
INTI · OTCMCIK 1042418fmd_1YACR9067Y28Q8X69WCQJEDT5QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Net interest income | 0 | 0 | 0 | 0 | 0 | (0) | – | – | – | – |
| Research and development | 3 | 2 | 3 | 1 | 0 | 0 | 0 | 1 | 2 | 2 |
| Total operating expenses | 7 | 5 | 5 | 3 | 1 | 0 | 1 | 3 | 4 | 3 |
| Operating income | (7) | (5) | (5) | (3) | (1) | (0) | (1) | (3) | (4) | (3) |
| Interest expense | – | – | – | – | – | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | – | (0) | 12 | (3) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Net income from continuing operations | – | – | – | – | – | (0) | 12 | – | – | – |
| Net income | (7) | (5) | (5) | (3) | (1) | (0) | 12 | (3) | (3) | (3) |
| Net income to common shareholders | – | – | – | – | – | (0) | 12 | (3) | – | – |